Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2015-07-27

FDA Approved: DIOVAN HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplement for Diovan HCT (valsartan with hydrochlorothiazide) submitted by Novartis, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Diovan HCT (valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for DIOVAN HCT (VALSARTAN AND HYDROCHLOROTHIAZIDE)